Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medexus Pharmaceuticals Inc MEDXF


Primary Symbol: T.MDP

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division’s prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division’s products include Rasuvo, IXINITY and Gleolan.


TSX:MDP - Post by User

Post by nozzpackon Aug 04, 2023 11:02am
109 Views
Post# 35573262

Q1 looks strong..Promoting it the next Week

Q1 looks strong..Promoting it the next Week

 

ORIGINAL: Medexus to Participate in Fireside Chat at SHARE Series Event

 

2023-08-04 07:00 ET - News Release

 

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 4, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will present at the SHARE Series event on Monday, August 14, 2023 at 8:30 AM Eastern time.

Event: SHARE Series
Date: August 14, 2023
Location: Virtual Presentation

Medexus Presentation: Monday, August 14 at 8:30 AM Eastern time

Ken d'Entremont, Medexus's Chief Executive Officer, and Marcel Konrad, Medexus's Chief Financial Officer, will conduct a 30-minute moderated fireside chat at 8:30 AM Eastern time. This fireside chat will include the opportunity for questions.

The live stream of the Medexus presentation will be available on the Investors—News & Events section of Medexus's corporate website or at the following link:

https://www.openexchange.tv/share-series

An archived replay will be available on the SHARE Series website for approximately 90 days following the event. 

About Medexus

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca

 

<< Previous
Bullboard Posts
Next >>